Investigating the association between IL-6 antagonist therapy and blood coagulation in critically ill patients with COVID-19: a protocol for a prospective, observational, multicentre study

Emőke Henrietta Kovács, Máté Rottler, Fanni Dembrovszky, Klementina Ocskay, László Szabó, Péter Hegyi, Zsolt Molnár, Krisztián Tánczos, Emőke Henrietta Kovács, Máté Rottler, Fanni Dembrovszky, Klementina Ocskay, László Szabó, Péter Hegyi, Zsolt Molnár, Krisztián Tánczos

Abstract

Introduction: Hypercoagulation is one the main features of COVID-19. It is induced by the hyperinflammatory response that shifts the balance of haemostasis towards pro-coagulation. Interleukin-6 (IL-6) antagonist therapy has been recommended in certain subgroups of critically ill patients with COVID-19 to modulate inflammatory response. The interaction between immune response and haemostasis is well recognised. Therefore, our objective is to evaluate whether the modulation of the inflammatory response by IL-6 antagonist inflicts any changes in whole blood coagulation as assessed by viscoelastic methods in critically ill patients with COVID-19.

Methods and analysis: In this prospective observational study, we are going to collect data on inflammatory parameters and blood coagulation using the ClotPro® device. The primary outcome is the change of the fibrinolytic system measured by the Lysis Time and Lysis onset time before and after immunomodulation therapy. Data will be collected before the IL-6 antagonist administration at baseline (T0) then after 24, 48 hours, then on day 5 and 7 (T1-4, respectively). Secondary outcomes include changes in other parameters related to inflammation, blood coagulation and biomarkers of endothelial injury.

Ethics and dissemination: Ethical approval was given by the Medical Research Council of Hungary (1405-3/2022/EÜG). All participants provided written consent. The results of the study will be disseminated through peer-reviewed journals.

Trial registration number: NCT05218369; Clinicaltrials.gov.

Keywords: Adult intensive & critical care; Bleeding disorders & coagulopathies; COVID-19.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

References

    1. Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med 2020;8:e46–7. 10.1016/S2213-2600(20)30216-2
    1. Llitjos J-F, Leclerc M, Chochois C, et al. . High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost 2020;18:1743–6. 10.1111/jth.14869
    1. Levy JH, Iba T, Olson LB, et al. . COVID-19: thrombosis, thromboinflammation, and anticoagulation considerations. Int J Lab Hematol 2021;43 Suppl 1:29–35. 10.1111/ijlh.13500
    1. Cuker A, Tseng EK, Nieuwlaat R, et al. . American society of hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients. Blood Adv 2022;6:4915–23. 10.1182/bloodadvances.2022007561
    1. National Iinstitute of Health COVID-19 Treatment Guidelines . Antithrombotic therapy in patients with COVID-19, 2022. Available: [Accessed 23 Aug 2022].
    1. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2006;2:619–26. 10.1038/ncprheum0338
    1. Hou T, Tieu BC, Ray S, et al. . Roles of IL-6-gp130 signaling in vascular inflammation. Curr Cardiol Rev 2008;4:179–92. 10.2174/157340308785160570
    1. Bester J, Pretorius E. Effects of IL-1β, IL-6 and IL-8 on erythrocytes, platelets and clot viscoelasticity. Sci Rep 2016;6. 10.1038/srep32188
    1. D'Alessandro A, Thomas T, Dzieciatkowska M, et al. . Serum proteomics in COVID-19 patients: altered coagulation and complement status as a function of IL-6 level. J Proteome Res 2020;19:4417–27. 10.1021/acs.jproteome.0c00365
    1. COVID-19 Treatment Guidelines Panel . Coronavirus disease 2019 (COVID-19) treatment guidelines National Institutes of Health; 2022. [Accessed 18 Aug 2022].
    1. World Health Organization . Therapeutics and COVID-19: living guideline; 2021. [Accessed 6 July 2021].
    1. Rockwood K, Song X, MacKnight C, et al. . A global clinical measure of fitness and frailty in elderly people. CMAJ 2005;173:489–95. 10.1503/cmaj.050051
    1. Rockwood K, Theou O. Using the clinical frailty scale in allocating scarce health care resources. Can Geriatr J 2020;23:254–9. 10.5770/cgj.23.463
    1. Bachler M, Bösch J, Stürzel DP, et al. . Impaired fibrinolysis in critically ill COVID-19 patients. Br J Anaesth 2021;126:590–8. 10.1016/j.bja.2020.12.010
    1. Hungarian Ministry of Human Resources (Emberi Erőforrások Minisztériuma) . Basics of the treatment of confirmed COVID-19 infected adults (Igazolt COVID-19 fertőzött felnőttek kezelésének alapjai). In: Handbook for the prevention and treatment of new coronavirus (SARS-CoV-2) infections (COVID-19) identified in 2020 a 2020. Évben azonosított új koronavírus (SARS-CoV-2) okozta fertőzések (COVID-19) megelőzésének és terápiájának kézikönyve) (IV/10948-8/2020/EGPOL), 2022.
    1. von Elm E, Altman DG, Egger M, et al. . The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Bull World Health Organ 2007;85:867–72. 10.2471/BLT.07.045120
    1. Darif D, Hammi I, Kihel A, et al. . The pro-inflammatory cytokines in COVID-19 pathogenesis: what goes wrong? Microb Pathog 2021;153:104799. 10.1016/j.micpath.2021.104799
    1. Cortegiani A, Ippolito M, Greco M, et al. . Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review. Pulmonology 2021;27:52–66. 10.1016/j.pulmoe.2020.07.003
    1. Tang N, Li D, Wang X, et al. . Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020;18:844–7. 10.1111/jth.14768
    1. Iba T, Warkentin TE, Thachil J, et al. . Proposal of the definition for covid-19-associated coagulopathy. J Clin Med 2021;10:191. 10.3390/jcm10020191
    1. Bareille M, Hardy M, Douxfils J, et al. . Viscoelastometric testing to assess hemostasis of COVID-19: a systematic review. J Clin Med 2021;10:10. 10.3390/jcm10081740
    1. Shen L, Tabaie S, Ivascu N. Viscoelastic testing inside and beyond the operating room. J Thorac Dis 2017;9:S299–308. 10.21037/jtd.2017.03.85
    1. Liu Z, Li J, Chen D, et al. . Dynamic interleukin-6 level changes as a prognostic indicator in patients with COVID-19. Front Pharmacol 2020;11:1093. 10.3389/fphar.2020.01093
    1. REMAP-CAP Investigators, Gordon AC, Mouncey PR, et al. . Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med 2021;384:1491–502. 10.1056/NEJMoa2100433
    1. Rubbert-Roth A, Furst DE, Nebesky JM, et al. . A review of recent advances using tocilizumab in the treatment of rheumatic diseases. Rheumatol Ther 2018;5:21–42. 10.1007/s40744-018-0102-x
    1. Tleyjeh IM, Kashour Z, Damlaj M, et al. . Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis. Clin Microbiol Infect 2021;27:215–27. 10.1016/j.cmi.2020.10.036
    1. Abani O, Abbas A, Abbas F, et al. . Tocilizumab in patients admitted to hospital with COVID-19 (recovery): a randomised, controlled, open-label, platform trial. The Lancet 2021;397:1637–45. 10.1016/S0140-6736(21)00676-0
    1. Ortega-Paz L, Galli M, Capodanno D. Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with covid-19: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J Cardiovasc Pharmacother 2021. 10.1093/ehjcvp/pvab070
    1. Salah HM, Mehta JL. Meta-analysis of the effect of aspirin on mortality in COVID-19. Am J Cardiol 2021;142:158–9. 10.1016/j.amjcard.2020.12.073
    1. Wang Y, Ao G, Nasr B, et al. . Effect of antiplatelet treatments on patients with COVID-19 infection: a systematic review and meta-analysis. Am J Emerg Med 2021;43:27–30. 10.1016/j.ajem.2021.01.016

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다